of MPN cases 5, 6 , MPL mutations occur somatically in about 1-5% of cases 7 , and somatic CALR mutations are found in about 20-30% of ET and PMF 8, 9 . Familial MPN is clinically indistinguishable from sporadic MPN, and displays frequent somatic JAK2 and CALR mutations 2, 3, [10] [11] [12] .
Other genes that frequently mutate somatically in MPN, such as TET2
13
, DNMT3A
14
, ASXL1
15
, etc., do not significantly contribute to familial MPN and in the majority of familial cases the causative germline mutation is unknown 16, 17 .
The role of common germline variants in MPN predisposition has been established.
Specifically, the JAK2 'GGCC' haplotype increases the risk to develop JAK2-mutant MPN by several fold 18 . Another germline variant in TERT (rs2736100) increases the risk of all molecular subtypes of MPN by ~2-fold 19, 20 . Both of these single nucleotide polymorphisms contribute to familial clustering of the disease, although they can explain In order to identify the germline mutation predisposing to MPN, we studied an Australian pedigree of English ancestry (Northern England) with five members in four generations diagnosed with MPN. DNA was available from three affected members ( Figure 1A) .
Each of the three members of the family has a different MPN-specific somatic mutation (JAK2-V617F, MPL-W515L, CALR-Type 1, Figure 1A ). To map the candidate disease loci in the pedigree, we applied a nonparametric algorithm SEGEX (Supplementary Table 2) .
To identify which of the RBBP6, C20orf3, and ARMC5 variants is the one predisposing to MPN, we examined healthy subjects for the presence of the candidate variants.
Based on this analysis, ARMC5-P507L was excluded due to 7% frequency in healthy controls while RBBP6-R1569H and C20orf3-D395N were not found in any of over 700 healthy controls. Figure 1D ) and one polymorphism in C20orf3 (P406L) present in 4% of the healthy subjects. Unfortunately, for both familial cases with RBBP6 mutation, DNA sample was available from only one affected member, therefore we could not obtain data on the mutation segregation with MPN for these two additional families. We used Polyphen 2 and SIFT mutation prediction tools to assess the possible effects of the mutations on protein function. RBBP6-R1569H is predicted to be damaging by both tools, while C20orf3-D395N mutation is benign (Supplementary Table 3 ). In summary,
C20orf3 is unlikely to be involved in familial MPN, whereas RBBP6 mutations remain strong candidates for familial predisposition to MPN.
Due to the low penetrance associated with RBBP6 mutations, establishing the family history of MPN may often be difficult. Therefore, we screened for RBBP6 mutations in 490 sporadic MPN cases. In this analysis we identified two unique germline mutations (S1444F and A1673V) in three apparently unrelated subjects and one polymorphism (I1661V) present in 0.5% of healthy controls (Table 1; Figure 1E ). Overall, we identified 5 different germline RBBP6 mutations associated with MPN and not detected in the general population (Table 1; Figure 1F ).
Apart from the three affected members, eight additional healthy family members carried RBBP6-R1569H in the Australian pedigree, consistent with the expected low penetrance 16 . Since common germline SNPs have been shown to contribute to familial 19 , we checked all members of the family for JAK2 GGCC haplotype and the rs2736100_C risk variant in TERT (Supplementary Table 4 ). As expected, from the affected members only the one with JAK2-V617F mutation was heterozygous for JAK2 GGCC haplotype, while two affected members were heterozygous for TERT risk variant and the third one was homozygous for the TERT risk allele. Although it is not possible to draw any solid conclusions based on a single family, we noticed a trend in JAK2 GGCC haplotype and TERT SNP distribution similar to the pattern we observed in our previous study 19 . The risk allele frequencies for both JAK2 GGCC haplotype and TERT rs2736100 were higher in RBBP6-R1569H mutant MPN patients compared to RBBP6-R1569H mutant unaffected members (16.67% vs. 6 .25% for JAK2 GGCC haplotype, 66.67% vs. 50.00% for TERT SNP).
We have identified germline RBBP6 mutations in about 5% of familial MPN cases (3/67) and in about 0.6% of sporadic cases (3/490) where family history is unknown. The low penetrance present in MPN pedigrees suggests that the disease is triggered by some stochastic factors, perhaps the acquisition of somatic mutations. In addition, common germline predisposition factors, such as JAK2 GGCC haplotype and TERT rs2736100 SNP seem to have an additive effect on the MPN risk in RBBP6 mutation carriers.
RBBP6 is a RING finger E3 ubiquitin ligase located in the nucleus. It has been reported to ubiquitinate and degrade p53, in association with MDM2. 22 As the RBBP6 mutations identified in our study were all located in the vicinity of its p53-binding domain ( Figure   1F ), they may affect p53 functions. It is likely that mutant RBBP6 causes an elevation in
For personal use only. on . by guest www.bloodjournal.org From 6 somatic mutagenesis rates through inhibition of p53 function and deregulation of cell cycle. The existence of somatic mutations in three hallmark MPN genes (JAK2, MPL and CALR) in a single family might be due to elevated mutagenesis in RBBP6 mutation carriers. Alternatively, RBBP6 mutations might enhance JAK-STAT signaling by a yet unknown mechanism, providing "fertile ground" for MPN development.
We cannot completely exclude the possibility that another unidentified mutation might be segregating with MPN phenotype in the family we studied due to insufficient coverage of some genomic regions by exome sequencing or the mutation being located in a noncoding region. However, our data suggests that RBBP6 is a candidate gene for 
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